All In Biotech

Drug Trial Radar · NCT07409428

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Mar 20, 2026

Primary completion

Apr 30, 2028

Study completion Dec 30, 2028

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Feb 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Conditions

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventions

  • HMPL-760Drug

    Patients will receive HMPL-760 once daily (QD) orally.

  • HMPL-760 PlaceboDrug

    Patients will receive HMPL-760 placebo once daily (QD) orally.

  • R-GemOxDrug

    R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Up to approximately two years
  2. End of treatment (EOT)Time frame: Up to approximately two years
  3. Systemic antitumor therapyTime frame: Up to approximately two years
  4. Overall survival (OS)Time frame: Up to approximately two years
  5. systematic anti-tumor therapyTime frame: Up to approximately two years
  6. Premature withdrawal from study treatmentTime frame: Up to approximately two years

Locations

51 sites in 1 country. Site status is shown where the registry gives one.

  • Baoding NO.1 Central Hospital

    Baoding, China · Recruiting

  • Beijing GoBroad Hospital

    Beijing, China · Recruiting

  • BEIJING TONGREN HOSPITAL, Capital Medical University

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • People's Hospital of Hunan Province

    Changsha, China · Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China · Recruiting

  • Quanzhou First Hospital.Fujian

    Fujian, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)

    Guangzhou, China · Recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University

    Hangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, China · Recruiting

  • Shandong Cancer Hospital & Institute

    Jinan, China · Recruiting

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, China · Not yet recruiting

  • Jiangxi Cancer Hospital

    Nanchang, China · Recruiting

  • Jiangsu Cancer Hospital

    Nanjing, China · Recruiting

  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

    Nanjing, China · Recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, China · Recruiting

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China · Recruiting

  • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine

    Shanghai, China · Not yet recruiting

  • Tongji Hospital of Tongji University

    Shanghai, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, China · Recruiting

  • Shenzhen people's hospital

    Shenzhen, China · Recruiting

  • Shanxi Provincial Cancer Hospital

    Taiyuan, China · Recruiting

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Tianjin People's Hospital

    Tianjin, China · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.